Pfizer: FDA grants pediatric exclusivity for Lyrica

(CercleFinance.com) - The US Food and Drug Administration (FDA) has ruled that Pfizer's neurological pain drug Lyrica is eligible for six months of pediatric exclusivity on the US market, until 30 June 2019.


Lyrica is currently approved in the US for fibromyalgia, diabetic nerve pain, spinal cord injury nerve pain and pain after shingles in adults.

In epileptic children, the drug is approved as adjunctive therapy for the treatment of partial onset seizures in patients of four years and above.

Pfizer expects to face generic competition for Lyrica in the US from 2019.

Copyright (c) 2018 CercleFinance.com. All rights reserved.